Anthera Pharmaceuticals, Inc. (ANTH)

[Paulieme]

Anthera Pharmaceuticals Inc (NASDAQ:ANTH) Given Consensus Rating of “Strong Buy” by Analysts
Posted by Taylor Nule on Mar 3rd, 2016-- Shares of Anthera Pharmaceuticals Inc (NASDAQ:ANTH) have earned a consensus broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Analysts have set a 1 year consensus price objective of $12.33 for the company and are forecasting that the company will post ($0.28) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Anthera Pharmaceuticals an industry rank of 71 out of 265 based on the ratings given to its competitors.
Anthera Pharmaceuticals (NASDAQ:ANTH) traded up 4.24% during mid-day trading on Thursday, reaching $3.69. The company’s stock had a trading volume of 437,261 shares. The company’s 50-day moving average price is $3.05 and its 200 day moving average price is $5.35. Anthera Pharmaceuticals has a 52 week low of $2.28 and a 52 week high of $11.65. The firm’s market capitalization is $147.14 million.


ANTH has been the topic of a number of research reports. Zacks Investment Research raised shares of Anthera Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Wednesday, November 4th. Jefferies Group reaffirmed a “buy” rating and set a $9.00 price target (down previously from $12.00) on shares of Anthera Pharmaceuticals in a research report on Friday, February 19th. Finally, Citigroup Inc. reduced their price target on shares of Anthera Pharmaceuticals from $15.00 to $11.00 in a research report on Friday, February 19th. http://lulegacy.com/?p=904123